In marked contrast, after intracerebral injection, anti-CD19 CAR-T cells invaded deeply into the solid tumor, reduced tumor growth, and induced regression of PCNSL, which was associated with long-term survival [15, 16]. The gene discussed is CD19; the disease is primary central nervous system lymphoma.